Evidence map›Paper›PMID 36996106›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Altered plasma membrane abundance of the sulfatide-binding protein NF155 links glycosphingolipid imbalances to demyelination.

Shannon J McKie, Alex S Nicholson, Emily Smith, Stuart Fawke, Eve R Caroe, James C Williamson, Benjamin G Butt, Denisa Kolářová, Ondřej Peterka, Michal Holčapek and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Shannon J McKieDepartment of Clinical Neuroscience, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.
Alex S NicholsonDepartment of Clinical Neuroscience, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.
Emily SmithDepartment of Clinical Neuroscience, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.ORCID 0000-0002-2419-6146
Stuart FawkeDepartment of Clinical Neuroscience, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.
Eve R CaroeDepartment of Clinical Neuroscience, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.ORCID 0000-0003-3529-024X
James C WilliamsonCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK.
Benjamin G ButtDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Denisa KolářováDepartment of Analytical Chemistry, University of Pardubice, Pardubice 53210, Czech Republic.ORCID 0000-0003-3749-625X
Ondřej PeterkaDepartment of Analytical Chemistry, University of Pardubice, Pardubice 53210, Czech Republic.
Michal HolčapekDepartment of Analytical Chemistry, University of Pardubice, Pardubice 53210, Czech Republic.ORCID 0000-0003-3978-1249
Paul J LehnerCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK.ORCID 0000-0001-9383-1054
Stephen C GrahamDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.ORCID 0000-0003-4547-4034
Janet E DeaneDepartment of Clinical Neuroscience, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.ORCID 0000-0002-4863-0330
University of Cambridge · GBUniversity of Pardubice · CZ

Funding

Medical Research Council MR/N020626/1Wellcome Trust 210688/Z/18/Z
6 · The paper itself

Abstract

Myelin is a multilayered membrane that tightly wraps neuronal axons, enabling efficient, high-speed signal propagation. The axon and myelin sheath form tight contacts, mediated by specific plasma membrane proteins and lipids, and disruption of these contacts causes devastating demyelinating diseases. Using two cell-based models of demyelinating sphingolipidoses, we demonstrate that altered lipid metabolism changes the abundance of specific plasma membrane proteins. These altered membrane proteins have known roles in cell adhesion and signaling, with several implicated in neurological diseases. The cell surface abundance of the adhesion molecule neurofascin (NFASC), a protein critical for the maintenance of myelin-axon contacts, changes following disruption to sphingolipid metabolism. This provides a direct molecular link between altered lipid abundance and myelin stability. We show that the NFASC isoform NF155, but not NF186, interacts directly and specifically with the sphingolipid sulfatide via multiple binding sites and that this interaction requires the full-length extracellular domain of NF155. We demonstrate that NF155 adopts an S-shaped conformation and preferentially binds sulfatide-containing membranes in

Indexed as

Demyelinating DiseasesSulfoglycosphingolipidsCarrier ProteinsCell Adhesion MoleculesGlycosphingolipidsHumansMyelin SheathNerve Growth FactorsCarrier ProteinsCell Adhesion MoleculesGlycosphingolipidsNerve Growth FactorsSulfoglycosphingolipidsgalactosylceramideKrabbe diseasemyelinneurofascinsulfatide

Identifiers

PMID36996106
PMCPMC10083573
OpenAlexW4361266887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.